Navigen Inc (AKA: Navigen Pharmaceuticals, Inc) Profile last edited on: 5/17/2018
CAGE: 4PV66
UEI: S8PXYJQM74M6
Business Identifier: Pharmaceutical and medical device company focused on advancing the most promising early-stage technologies into products 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 01
County: Salt Lake
Congr. District: 01
County: Salt Lake
Public Profile
Navigen is a pharmaceutical and medical device company focused on advancing the most promising early-stage technologies into products. Navigen's strategy is to partner with innovative and dedicated inventors to develop their technologies. Navigen has interests in new pharmaceutical and device technologies. The company does not target any specific size or stage of project.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2022 | 2 | NIH | $9,299,392 | |
| Project Title: Therapeutic D-Peptide Inhibitor of HIV Entry | ||||
| 2019 | 1 | NIH | $268,075 | |
| Project Title: Stabilization of the Alveolar-Capillary Barrier with ARF6 Inhibitor as a Treatment for Severe Influenza | ||||
| 2019 | 2 | NIH | $323,066 | |
| Project Title: Oral/Topical D-Peptide TNF Inhibitors for Inflammatory Bowel Disease | ||||
| 2018 | 2 | NIH | $1,931,372 | |
| Project Title: Treating Acute Lung Injury Via Cytokine Signaling Blockade | ||||
| 2018 | 2 | NIH | $3,584,327 | |
| Project Title: Protease-Resistant D-Peptide Inhibitors of RSV Entry | ||||
Key People / Management
Hunter Jackson -- Chairman and CEO
Dean Li -- Chief Scientific Officer
Alan L Mueller -- Vice President of Research
Sutip Navankasattusas
Kirill Ostanin
Brandi Simpson -- Chief Business Officer
Elizabeth Wang
Brett D Welch
Daniel A Wettstein
Dean Li -- Chief Scientific Officer
Alan L Mueller -- Vice President of Research
Sutip Navankasattusas
Kirill Ostanin
Brandi Simpson -- Chief Business Officer
Elizabeth Wang
Brett D Welch
Daniel A Wettstein
Company News
There are no news available.
